Reading File
Finding Sources
Finding Sources
Reading File
The textbook content confirms the analysis. Here is the full breakdown:
Answer: (a) 1, 3 and 4
Statement-by-Statement Analysis
Statement 1: PEG-IFN is poorly tolerated compared to nucleoside analogues - TRUE
Harrison's (2025) states that favoring oral nucleoside/nucleotide analogues includes "the absence of injections, difficult-to-tolerate side effects, and laboratory monitoring" associated with PEG-IFN. PEG-IFN requires subcutaneous injections and causes significant side effects (flu-like symptoms, cytopenias, neuropsychiatric effects) - far worse tolerability than oral agents like tenofovir or entecavir.
Statement 2: Resistance to PEG-IFN is common - FALSE
Resistance does NOT develop to interferons, because PEG-IFN works through immunomodulation rather than direct viral enzyme inhibition. Resistance is the major problem with nucleoside analogues (especially older ones like lamivudine). Harrison's explicitly states that PEG-IFN "does not support viral mutation" - meaning no resistance development. This is actually an advantage of PEG-IFN over nucleoside analogues.
Statement 3: PEG-IFN is not useful in cirrhosis - TRUE
PEG-IFN is contraindicated in decompensated cirrhosis and has very limited utility even in compensated cirrhosis, because interferon can precipitate hepatic decompensation. The immunostimulatory flares it triggers can be life-threatening in cirrhotic patients with limited hepatic reserve.
Statement 4: PEG-IFN is administered every week for 48 weeks - TRUE
Harrison's confirms: "PEG IFN-α2a (180 μg weekly for 48 weeks)" is the standard regimen. This is well-established.
Summary Table
| Statement | Claim | Verdict |
|---|---|---|
| 1 | PEG-IFN poorly tolerated vs nucleoside analogues | ✅ TRUE |
| 2 | Resistance to PEG-IFN is common | ❌ FALSE (resistance doesn't occur with IFN) |
| 3 | PEG-IFN not useful in cirrhosis | ✅ TRUE |
| 4 | Weekly for 48 weeks | ✅ TRUE |
Correct statements: 1, 3, 4 → Answer: (a)
- Harrison's Principles of Internal Medicine 22E, Current First-Line Treatment Options (Hepatitis B)
Finding Sources
Finding Sources
Reading File
Harrison's provides the definitive table directly. Here is the complete answer:
Answer: (a)
Distal latency is normal in axonal degeneration and prolonged in segmental demyelination
Full NCS Comparison Table (from Harrison's Principles of Internal Medicine, 22nd Ed.)
| Parameter | Axonal Degeneration | Segmental Demyelination |
|---|---|---|
| CMAP amplitude | Decreased | Normal (except with conduction block) |
| Distal latency | Normal | Prolonged |
| Conduction velocity | Normal | Slow |
| Conduction block | Absent | Present |
| Temporal dispersion | Absent | Present |
| F wave | Normal or absent | Prolonged or absent |
| SNAP amplitude | Decreased | Normal or decreased |
| Fibrillations on EMG | Present | Absent |
Why the other options are wrong
- (b) Conduction velocity is slow in demyelination (not axonal degeneration) - it's the opposite. In axonal loss, myelin is intact so velocity is preserved.
- (c) Conduction block is a feature of demyelination (present), not axonal degeneration (absent).
- (d) Temporal dispersion is a feature of demyelination, not axonal degeneration.
The key concept
In axonal degeneration, the myelin sheath is relatively preserved, so saltatory conduction speed (velocity and latency) remains normal. What decreases is the amplitude of the signal because fewer axons are conducting. In demyelination, the myelin is damaged, slowing conduction and prolonging latencies - but axons survive so amplitude is relatively preserved.
Harrison's adds: "The presence of nonuniform slowing of conduction velocity, conduction block, or temporal dispersion further suggests an acquired demyelinating neuropathy (e.g., GBS or CIDP) as opposed to a hereditary one (e.g., CMT type 1)."
- Harrison's Principles of Internal Medicine 22E, Table 457-3, Electrodiagnostic Studies
Finding Sources
Finding Sources
Reading File
Finding Sources
The textbooks confirm everything. Here is the full breakdown:
Answer: (c)
Their glucose-lowering effect is dependent on insulin secretion and insulin sensitivity - FALSE → This is actually the CORRECT/TRUE statement about SGLT2 inhibitors being insulin-INDEPENDENT
Wait - let me re-read option (c) carefully: "Their glucose-lowering effect is dependent on insulin secretion and insulin sensitivity" - this is FALSE. SGLT2 inhibitors work independently of insulin.
So option (c) is the incorrect statement about SGLT2 inhibitors, making it the one that "distinguishes" them from the others... but the question asks which statement is TRUE.
Re-reading all options with textbook evidence:
Statement-by-Statement Analysis
Option (a): "They are used in type 1, type 2, and pancreatogenic forms of DM" - FALSE
SGLT2 inhibitors are approved for type 2 DM primarily. Their use in type 1 DM is off-label and actually carries a significantly increased risk of DKA. Goldman-Cecil confirms: "increased risk of diabetic ketoacidosis, especially when used in patients with type 1 diabetes." Pancreatogenic DM is also not a standard indication.
Option (b): "They cause increase in blood pressure by 3-6 mmHg" - FALSE
The opposite is true. Goodman & Gilman's states: "decrease blood pressure by 2 to 4 mmHg." Goldman-Cecil confirms: "SGLT2 inhibitor-mediated natriuresis and glucosuria lower cardiac preload." BP goes down, not up.
Option (c): "Their glucose-lowering effect is dependent on insulin secretion and insulin sensitivity" - FALSE
Goldman-Cecil explicitly states: "This primary renal effect of SGLT2 inhibitors is independent of insulin." Brenner & Rector's The Kidney states: "Because the renal mechanism of action of SGLT2 inhibitors is independent of insulin, their efficacy is not declining with progressive β-cell dysfunction and/or insulin resistance." This is a defining feature of SGLT2 inhibitors.
Option (d): "Euglycemic diabetic ketoacidosis may occur during treatment if there is a concurrent illness" - TRUE ✅
Multiple textbooks confirm this. Fuster & Hurst's The Heart: "diabetic ketoacidosis at relatively normal glucose levels ('euglycemic diabetic ketoacidosis') can also occur with SGLT2 inhibitors." Miller's Anesthesia: "euglycemic ketoacidosis can be precipitated by a fasting state" - illness/fasting triggers it by shifting metabolism toward ketogenesis while glucose remains near-normal due to glycosuria masking hyperglycemia.
Answer: (d)
Euglycemic DKA with SGLT2 inhibitors during concurrent illness is the TRUE statement.
| Option | Claim | Verdict |
|---|---|---|
| (a) | Used in type 1, type 2, pancreatogenic DM | ❌ False - mainly type 2 |
| (b) | Increases BP by 3-6 mmHg | ❌ False - decreases BP by 2-4 mmHg |
| (c) | Glucose-lowering is insulin-dependent | ❌ False - it is insulin-independent |
| (d) | Euglycemic DKA may occur during concurrent illness | ✅ TRUE |
The mechanism: SGLT2 inhibitors increase glucagon, promote lipolysis, and cause ketogenesis. During illness (starvation, surgery, infection), these effects are amplified. Glucose appears normal (euglycemic) because the drug is actively causing glycosuria - masking the true metabolic crisis. This is why SGLT2 inhibitors should be held 3-4 days before surgery.
- Goldman-Cecil Medicine, Sodium-Glucose Cotransporter 2 Inhibitors
- Goodman & Gilman's Pharmacological Basis of Therapeutics, SGLT2 Inhibitors
- Miller's Anesthesia 10e, Perioperative Diabetes Management
Finding Sources
Finding Sources
Reading File
Finding Sources
The textbooks confirm the analysis clearly. Here is the complete answer:
Answer: (d) 2, 3 and 4
Understanding the Pathophysiology First
During chemotherapy, massive tumor cell destruction releases purines, which are metabolized to uric acid via xanthine oxidase. This uric acid is filtered by the kidneys and precipitates in the renal tubules as insoluble crystals, causing intratubular obstruction, vasoconstriction, and acute kidney injury (tumor lysis syndrome).
Prevention = either reduce uric acid load or prevent its precipitation in tubules (via dilution or alkalinization).
Statement-by-Statement Analysis
1. Probenecid - NOT useful ❌
Probenecid is a uricosuric drug - it blocks uric acid reabsorption in the proximal tubule (URAT1), increasing uric acid excretion into the urine. In the context of tumor lysis, this would dump even more uric acid into the very tubules where crystal deposition is already the problem - potentially worsening nephropathy. It is contraindicated here.
2. Forced saline diuresis - Useful ✅
Vigorous IV hydration with normal saline increases urine flow, diluting uric acid concentration in the tubules and physically flushing crystals out before they precipitate. Brenner & Rector's confirms aggressive volume expansion is a core preventive strategy for tumor lysis syndrome.
3. Rasburicase - Useful ✅
Rasburicase (recombinant urate oxidase) converts uric acid to allantoin, which is far more water-soluble and easily excreted. Brenner & Rector's: "Rasburicase catalyzes the degradation of uric acid to allantoin and has been shown to be effective both as prophylaxis and treatment for acute uric acid-mediated tumor lysis syndrome." This is the most potent agent available - it can normalize uric acid within hours.
4. Acetazolamide - Useful ✅
Acetazolamide is a carbonic anhydrase inhibitor that alkalinizes the urine (makes it less acidic). Uric acid is much more soluble at higher pH - alkaline urine prevents crystal precipitation in the tubules. Classic tumor lysis prevention protocols include urine alkalinization alongside hydration and allopurinol/rasburicase.
Summary Table
| Drug | Mechanism | Effect on Uric Acid Nephropathy |
|---|---|---|
| Probenecid | Uricosuric (↑ urinary uric acid) | ❌ Harmful - worsens tubular uric acid load |
| Forced saline diuresis | Dilutes & flushes uric acid | ✅ Prevents crystal deposition |
| Rasburicase | Converts uric acid → allantoin | ✅ Most effective - reduces uric acid load |
| Acetazolamide | Alkalinizes urine | ✅ Increases uric acid solubility |
Answer: (d) 2, 3 and 4
- Brenner and Rector's The Kidney, Tumor Lysis Syndrome & Prevention of Intrinsic AKI
- Harrison's Principles of Internal Medicine 22E, Uric Acid Nephropathy in Chemotherapy
- Rheumatology (Elsevier), Renal Handling of Urate
Finding Sources
Finding Sources
Multiple authoritative textbooks confirm this unanimously. Here is the complete answer:
Answer: (d) 1, 2 and 3
HAND is a spectrum of three disorders, all three of which are included under this umbrella term.
The Three Components of HAND (Frascati Criteria, 2007)
| # | Category | Description |
|---|---|---|
| 1 | Asymptomatic Neurocognitive Impairment (ANI) | Abnormal neuropsychological test results in ≥2 cognitive domains, but no functional impairment in daily life. Most common form. |
| 2 | Mild Neurocognitive Disorder (MND) | Cognitive deficits with mild functional impairment (e.g., reduced work efficiency). |
| 3 | HIV-Associated Dementia (HAD) | Severe cognitive deficits with marked functional impairment - the most severe but now least common form in the ART era. |
Harrison's states: "The term HIV-associated neurocognitive disorders (HAND) is used to describe a spectrum of disorders that range from asymptomatic neurocognitive impairment (ANI) to minor neurocognitive disorder (MND) to clinically severe dementia. The most severe form, HIV-associated dementia (HAD)..."
The Maudsley Prescribing Guidelines confirm: "HAND encompasses three sub-disorders, ranging from the more common asymptomatic neurocognitive impairment (ANI) to a mild neurocognitive disorder (MND) and the more severe but less common HIV-associated dementia (HAD)."
Key Points to Remember
- The spectrum goes from mildest (ANI) → moderate (MND) → most severe (HAD)
- In the modern ART era, ANI and MND are the predominant forms; frank HAD is now uncommon
- All three are diagnosed after excluding other causes (opportunistic infections, metabolic causes, medications)
- Diagnosis requires neuropsychological testing across multiple cognitive domains
Answer: (d) 1, 2 and 3 - all three are components of HAND.
- Harrison's Principles of Internal Medicine 22E, HIV-Associated Neurocognitive Disorders
- The Maudsley Prescribing Guidelines in Psychiatry, 15th ed.
- Grainger & Allison's Diagnostic Radiology, HIV Encephalopathy (2007 Frascati Classification)
Finding Sources
Finding Sources
Finding Sources
Finding Sources
All four statements are now confirmed from textbooks. Here is the complete answer:
Answer: (a) 1 and 2
Statement-by-Statement Analysis
Statement 1: It parasitizes the mucosa of the upper part of the small intestine - TRUE ✅
Strongyloides stercoralis adult female worms embed in the mucosa of the duodenum and jejunum (upper small intestine). Sleisenger & Fordtran confirms: "mucosal infiltration and ulceration in the duodenum and jejunum." This is where the parthenogenetic females live and lay eggs.
Statement 2: Larva currens is a fast-moving transient rash seen across abdomen and buttocks - TRUE ✅
Fitzpatrick's Dermatology confirms larva currens is "a migratory serpiginous and intensely pruritic lesion caused by intradermal migration of larvae" moving at up to 5-10 cm/hour (much faster than cutaneous larva migrans from hookworm). It typically starts in the perianal area and tracks rapidly across the buttocks, trunk, and abdomen - the hallmark skin finding of strongyloidiasis.
Statement 3: Ivermectin is NOT an effective treatment - FALSE ❌
Ivermectin is the drug of choice for strongyloidiasis. Dermatology (5e) states: "Ivermectin is the treatment of choice for disseminated strongyloidiasis." It is superior to albendazole and thiabendazole (Cochrane review confirms this). Statement 3 is completely wrong.
Statement 4: Systemic strongyloidiasis is seen in immune competent state - FALSE ❌
The opposite is true. Lippincott Pharmacology states: "Hyperinfection syndrome and disseminated strongyloidiasis are typically seen in immunocompromised patients" - such as those with HTLV-1 infection, on chronic corticosteroids, post-transplant, or with AIDS. In immunocompetent hosts, the worm burden is controlled and infection remains low-grade/chronic.
Summary
| Statement | Verdict |
|---|---|
| 1 - Parasitizes upper small intestine (duodenum/jejunum) | ✅ TRUE |
| 2 - Larva currens = fast-moving rash on abdomen/buttocks | ✅ TRUE |
| 3 - Ivermectin is NOT effective | ❌ FALSE (it IS the drug of choice) |
| 4 - Systemic disease in immunocompetent | ❌ FALSE (requires immunocompromised state) |
Answer: (a) 1 and 2
- Sleisenger & Fordtran's Gastrointestinal and Liver Disease, Helminthic Infections
- Fitzpatrick's Dermatology, Strongyloidiasis & Larva Currens
- Lippincott Illustrated Reviews Pharmacology, Ivermectin
- Dermatology 2-Volume Set 5e, Disseminated Strongyloidiasis
This is a shared conversation. Sign in to Orris to start your own chat.